- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Revelation Biosciences, Inc. plans to engage the FDA regarding approval pathways and has enrolled cohorts in a clinical study in the US.
1 report, 1 independent
Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Revelation Biosciences, Inc. plans to engage the FDA regarding approval pathways and has enrolled cohorts in a clinical study in the US.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- FDA approval expands patient access to therapies for ACCORD.
- Expertise is guiding drug development toward regulatory approval, involving the FDA and David Rubenstein.
- FDA provided guidance for HCW Biologics' IND application.
- FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
Coverage
Newest first; wire copies grouped- Business WireRevelation Biosciences Inc. Completes Dosing of Patients in PRIME Study – Sample analysis and data collection ongoing – – Data expected during Q3 2025 – SAN DIEGO, July 16, 2025--(BUSINESS WIRE)--Rev